ICCM

ICCM

USD

IceCure Medical Ltd. Ordinary Shares

$0.728+0.000 (0.069%)

Цена в режиме реального времени

Healthcare
Медицинские приборы
Израиль

График цен

Loading Chart...

Ключевые показатели

Рыночные показатели
Фундаментальные показатели компании
Статистические данные торговли

Рыночные показатели

Открытие

$0.728

Максимум

$0.740

Минимум

$0.714

Объем

0.13M

Фундаментальные показатели компании

Рыночная капитализация

50.2M

Отрасль

Медицинские приборы

Страна

Israel

Статистические данные торговли

Средний объем

1.68M

Биржа

NCM

Валюта

USD

52-недельный диапазон

Минимум $0.534Текущая $0.728Максимум $1.66

Связанные новости

PR Newswire

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...

Просмотреть больше
IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Icecure Medical, Raises Price Target to $2.5

HC Wainwright & Co. analyst Yi Chen maintains Icecure Medical with a Buy and raises the price target from $2 to $2.5.

Просмотреть больше
HC Wainwright & Co. Maintains Buy on Icecure Medical, Raises Price Target to $2.5
PR Newswire

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

The U.S. Food and Drug Administration ("FDA") has granted marketing authorization for ProSense®, a minimally invasive cryoablation treatment for...

Просмотреть больше
IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care
PR Newswire

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...

Просмотреть больше
IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

Оставаться в курсе

Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.